TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01150513
Drug: EC-T
Normalized name: Spec-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Study: NCT01150513
Drug: TP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Study: NCT01314222
Drug: Placebo matching BMS-954561
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01677403
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nebulised 80mg twice daily
Study: NCT00291733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tabl
Study: NCT04626765
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/㎡ for D-3 and D-2
Study: NCT00657917
Drug: Paromomycin +Gentamicin topical cream
Normalized name: gentamicin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
Study: NCT00689208
Drug: Placebo Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00574379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily for 14 days
Study: NCT00386100
Drug: Avandamet 8 mg/ 2000 mg (ttd)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
Study: NCT00730470
Drug: U3-1287 (AMG888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
Study: NCT00243815
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03027973
Drug: Placebo (for UPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic UPA 5 mg
Study: NCT03027973
Drug: Placebo (for TEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic TEA 500mg
Study: NCT02100813
Drug: LEO 43204
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02100813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01889303
Drug: concurrent chemoradiotherapy with 5-FU/CF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles.
Study: NCT02500667
Drug: N91115
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID
Study: NCT04652739
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
Study: NCT03138811
Drug: CSJ117
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled once daily dose
Study: NCT03138811
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled once daily dose
Study: NCT03247036
Drug: IV thrombolytic (t-PA) treatment vs not
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Stroke Protocol
Study: NCT03597971
Drug: HMPL004-6599
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each cohort, 6 subjects will receive HMPL004-6599
Study: NCT03597971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each cohort, 2 subjects will receive placebo
Study: NCT04159766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT01155284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
Study: NCT03042780
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
Study: NCT00727649
Drug: Psyllium powder
Normalized name: psyllium Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
Study: NCT01584570
Drug: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECG monitoring for evaluation of QTc interval
Study: NCT03279471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
Study: NCT03767244
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
Study: NCT03767244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo oral tablets daily.
Study: NCT02991261
Drug: SPARC001 type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type I
Study: NCT02991261
Drug: SPARC001 type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type II
Study: NCT04557163
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 will be given as 1 mg per capsule administered orally with water.
Study: NCT02991261
Drug: Reference001 type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen
Study: NCT02991261
Drug: Reference001 type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone Acetaminophen
Study: NCT03655002
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04112498
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on Specified days
Study: NCT02274038
Drug: Baseline 18F-thymidine (FLT) PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
Study: NCT02274038
Drug: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare.
Study: NCT02274038
Drug: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
Study: NCT03007147
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01332513
Drug: Investigational Medicinal Product (MR1)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
Study: NCT01332513
Drug: Investigational Medicinal Product (MR2)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
Study: NCT01332513
Drug: Investigational Medicinal Product (MR3)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
Study: NCT03007147
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03007147
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01332513
Drug: Investigational Medicinal Product (MR4)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
Study: NCT03007147
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01332513
Drug: Investigational Medicinal Product (MR5)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
Study: NCT03007147
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT01332513
Drug: Investigational Medicinal Product (IR)
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
Study: NCT03007147
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03007147
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT03559426
Drug: Antipsychotic Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
Study: NCT03559426
Drug: Antipsychotic Maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
Study: NCT04093570
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 film-coated, immediate-release FDC tablets
Study: NCT03497988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
Study: NCT00760396
Drug: VGX-1027
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will
Study: NCT00213031
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02882373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02114775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
Study: NCT02201511
Drug: 3 mg PF-06412562 MR tablets_Fasted
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
Study: NCT02201511
Drug: 2 x 15 mg PF-06412562 MR tablets_Fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
Study: NCT02201511
Drug: 2 x 15 mg PF-06412562 MR tablets_Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
Study: NCT02201511
Drug: 10 mg PF-06412562 IR tablets
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
Study: NCT00423696
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00423696
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00423696
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04290390
Drug: Segesterone Acetate and Ethinyl Estradiol
Normalized name: ETHINYL ESTRADIOL/SEGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive Vaginal System
Study: NCT01794533
Drug: Lidocaine with Epinephrine+ Normal saline
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
Study: NCT01794533
Drug: Lidocaine with Epinephrine + fentanyl
Normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
Study: NCT00665717
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet; QD; 4 days
Study: NCT00665717
Drug: Pravastatin and raltegravir
Normalized name: lamivudine and raltegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
Study: NCT04087707
Drug: Step 1: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Study: NCT04087707
Drug: Step 2: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Study: NCT04087707
Drug: Step 2: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly participants will receive placebo once daily for 7 consective days
Study: NCT04449471
Drug: Naproxen tablet
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
Study: NCT04573153
Drug: Hydroxychloroquine + Sorbitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
Study: NCT00667498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Study: NCT05155072
Drug: DW1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1903
Study: NCT05155072
Drug: DW1903-R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1903-R2
Study: NCT03533582
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03533582
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01358708
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
Study: NCT03978689
Drug: CUE-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
Study: NCT00540098
Drug: Placebo + aerobic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill once daily + regular aerobic exercise
Study: NCT00540098
Drug: Placebo + relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill once daily + regular relaxation training
Study: NCT01377285
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan
Study: NCT03119701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilisate for solution for injection as placebo.
Study: NCT00051636
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
Study: NCT00051636
Drug: Placebo to Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mL of sterile water one dose intravenous infusion.
Study: NCT05594316
Drug: Trichloroacetic acid
Normalized name: Trichloroacetic Acid
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
Study: NCT03684980
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
Study: NCT03684980
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
Study: NCT02672917
Drug: modified FOLFIRINOX (mFOLFIRINOX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01146431
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
Study: NCT01146431
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
Study: NCT04536467
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard chemotherapy
Study: NCT00177099
Drug: FK506, GP11046, GP11511
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04427709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo injection
Study: NCT03932435
Drug: Fisrt period TWLO_C
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Study: NCT03932435
Drug: Fisrt period TWLO
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Study: NCT03932435
Drug: Second period TWLO_C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Study: NCT01190826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once by inhalation